Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Orca Bio

Request full access

Precision cell therapies for blood cancer transplants

North Fair Oaks, United StatesFounded 2016Biotech & Life Sciences

About Orca Bio

Orca Bio is a commercial-stage biotechnology company based in Menlo Park, California, that develops high-precision allogeneic cell therapies for blood cancers and other serious diseases of the blood and immune system. The company was founded in 2016 by scientists and operators from Stanford University's stem cell research community, and its work centres on improving allogeneic hematopoietic stem cell transplantation, a potentially curative but often toxic procedure used to treat leukemias and related disorders.

At the core of the company is a proprietary manufacturing platform that sorts donor blood with single-cell precision. Instead of infusing a largely unprocessed graft, Orca Bio isolates and combines defined populations of regulatory T cells, hematopoietic stem and progenitor cells and conventional T cells, producing a personalised product for each patient. The aim is to replace a patient's diseased blood and immune system with a healthy one while lowering the risk of graft-versus-host disease and reducing the need for broad immunosuppression.

The company's lead product, TREGZI, known in clinical development as Orca-T, received U.S. FDA approval in June 2026 for use in matched-donor stem cell transplantation in adults with hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes. Its second-generation candidate, Orca-Q, is being studied in haploidentical and mismatched donor settings, and both therapies are being evaluated with reduced-intensity and nonmyeloablative conditioning to reach older or less fit patients.

Orca Bio serves transplant centres, hematologists and oncologists, and runs its own cell processing and manufacturing operations in Sacramento, California, with additional East Coast capacity planned to support commercial scale. Its pipeline also targets autoimmune diseases that could benefit from immune system reset.

Source: Dealroom company data

Orca Bio in the North Fair Oaks ecosystem

Live from Dealroom

The Orca Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A1 investor entered at this stage

Series B and later6 investors entered at this stage

Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$11M

8 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Orca Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.